These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

198 related items for PubMed ID: 11793169

  • 1. Effect of menatetrenone on bone mineral density and incidence of vertebral fractures in postmenopausal women with osteoporosis: a comparison with the effect of etidronate.
    Iwamoto J, Takeda T, Ichimura S.
    J Orthop Sci; 2001; 6(6):487-92. PubMed ID: 11793169
    [Abstract] [Full Text] [Related]

  • 2. Effects of cyclical etidronate with alfacalcidol on lumbar bone mineral density, bone resorption, and back pain in postmenopausal women with osteoporosis.
    Iwamoto J, Takeda T, Ichimura S, Matsu K, Uzawa M.
    J Orthop Sci; 2003; 8(4):532-7. PubMed ID: 12898306
    [Abstract] [Full Text] [Related]

  • 3. Effects of 5-year treatment with elcatonin and alfacalcidol on lumbar bone mineral density and the incidence of vertebral fractures in postmenopausal women with osteoporosis: a retrospective study.
    Iwamoto J, Takeda T, Ichimura S, Uzawa M.
    J Orthop Sci; 2002; 7(6):637-43. PubMed ID: 12486466
    [Abstract] [Full Text] [Related]

  • 4. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis.
    Watts NB, Harris ST, Genant HK, Wasnich RD, Miller PD, Jackson RD, Licata AA, Ross P, Woodson GC, Yanover MJ.
    N Engl J Med; 1990 Jul 12; 323(2):73-9. PubMed ID: 2113611
    [Abstract] [Full Text] [Related]

  • 5. A comparison of the effect of risedronate and etidronate on lumbar bone mineral density in Japanese patients with osteoporosis: a randomized controlled trial.
    Fukunaga M, Kushida K, Kishimoto H, Shiraki M, Taketani Y, Minaguchi H, Inoue T, Morita R, Morii H, Yamamoto K, Ohashi Y, Orimo H, Risedronate Phase III Research Group.
    Osteoporos Int; 2002 Dec 12; 13(12):971-9. PubMed ID: 12459940
    [Abstract] [Full Text] [Related]

  • 6. Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: three years of blinded therapy followed by one year of open therapy.
    Harris ST, Watts NB, Jackson RD, Genant HK, Wasnich RD, Ross P, Miller PD, Licata AA, Chesnut CH.
    Am J Med; 1993 Dec 12; 95(6):557-67. PubMed ID: 8259772
    [Abstract] [Full Text] [Related]

  • 7. The use of etidronate and calcium versus calcium alone in the treatment of postmenopausal osteopenia: results of three years of treatment.
    Montessori ML, Scheele WH, Netelenbos JC, Kerkhoff JF, Bakker K.
    Osteoporos Int; 1997 Dec 12; 7(1):52-8. PubMed ID: 9102064
    [Abstract] [Full Text] [Related]

  • 8. A four-year randomized controlled trial of hormone replacement and bisphosphonate, alone or in combination, in women with postmenopausal osteoporosis.
    Wimalawansa SJ.
    Am J Med; 1998 Mar 12; 104(3):219-26. PubMed ID: 9552083
    [Abstract] [Full Text] [Related]

  • 9. Five years of clinical experience with intermittent cyclical etidronate for postmenopausal osteoporosis.
    Storm T, Kollerup G, Thamsborg G, Genant HK, Sørensen OH.
    J Rheumatol; 1996 Sep 12; 23(9):1560-4. PubMed ID: 8877926
    [Abstract] [Full Text] [Related]

  • 10. Effects of combined treatment with etidronate, nandrolone-decanoate and calcium on bone mineral density in postmenopausal women.
    Bolanca S, Korsić M, Dekanić D, Cvijetić S.
    Acta Med Croatica; 1998 Sep 12; 52(3):159-63. PubMed ID: 9818438
    [Abstract] [Full Text] [Related]

  • 11. Predicting subsequent bone density response to intermittent cyclical therapy with etidronate from initial density response in patients with osteoporosis.
    Crilly RG, Sebaldt RJ, Hodsman AB, Adachi JD, Brown JP, Goldsmith CH, Hanley DA, Olszynski WO, Ste-Marie LG, Stephenson GF.
    Osteoporos Int; 2000 Sep 12; 11(7):607-14. PubMed ID: 11069195
    [Abstract] [Full Text] [Related]

  • 12. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis.
    Storm T, Thamsborg G, Steiniche T, Genant HK, Sørensen OH.
    N Engl J Med; 1990 May 03; 322(18):1265-71. PubMed ID: 2109197
    [Abstract] [Full Text] [Related]

  • 13. Comparison of effect of treatment with etidronate and alendronate on lumbar bone mineral density in elderly women with osteoporosis.
    Iwamoto J, Takeda T, Sato Y, Uzawa M.
    Yonsei Med J; 2005 Dec 31; 46(6):750-8. PubMed ID: 16385649
    [Abstract] [Full Text] [Related]

  • 14. Effect of intermittent cyclical etidronate therapy on corticosteroid induced osteoporosis in Japanese patients with connective tissue disease: 3 year followup.
    Sato S, Ohosone Y, Suwa A, Yasuoka H, Nojima T, Fujii T, Kuwana M, Nakamura K, Mimori T, Hirakata M.
    J Rheumatol; 2003 Dec 31; 30(12):2673-9. PubMed ID: 14719212
    [Abstract] [Full Text] [Related]

  • 15. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group.
    Liberman UA, Weiss SR, Bröll J, Minne HW, Quan H, Bell NH, Rodriguez-Portales J, Downs RW, Dequeker J, Favus M.
    N Engl J Med; 1995 Nov 30; 333(22):1437-43. PubMed ID: 7477143
    [Abstract] [Full Text] [Related]

  • 16. Early response to alendronate after treatment with etidronate in postmenopausal women with osteoporosis.
    Iwamoto J, Takeda T, Ichimura S, Uzawa M.
    Keio J Med; 2003 Jun 30; 52(2):113-9. PubMed ID: 12862363
    [Abstract] [Full Text] [Related]

  • 17. Risedronate decreases bone resorption and improves low back pain in postmenopausal osteoporosis patients without vertebral fractures.
    Ohtori S, Akazawa T, Murata Y, Kinoshita T, Yamashita M, Nakagawa K, Inoue G, Nakamura J, Orita S, Ochiai N, Kishida S, Takaso M, Eguchi Y, Yamauchi K, Suzuki M, Aoki Y, Takahashi K.
    J Clin Neurosci; 2010 Feb 30; 17(2):209-13. PubMed ID: 20044258
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Cyclical etidronate plus ergocalciferol prevents glucocorticoid-induced bone loss in postmenopausal women.
    Diamond T, McGuigan L, Barbagallo S, Bryant C.
    Am J Med; 1995 May 30; 98(5):459-63. PubMed ID: 7733124
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.